All In Biotech

Drug Trial Radar · NCT02214160

Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies

An Open-label Long-Term Safety and Efficacy Extension Study in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies

Last checked: Nov 20, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

94

Actual

Start

Dec 9, 2014

Primary completion

Dec 3, 2020

Study completion Dec 3, 2020

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Aug 12, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term safety and efficacy of UX007 in participants with LC-FAOD. The secondary objectives of this study are to evaluate the effect of UX007 on energy metabolism in LC-FAOD and evaluate the impact of UX007 on clinical events associated with LC-FAOD.

Conditions

  • Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency
  • Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency
  • Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency
  • Trifunctional Protein (TFP) Deficiency
  • Carnitine-acylcarnitine Translocase (CACT) Deficiency

Interventions

  • UX007Drug

    Administered orally (PO) with food or by gastrostomy tube, at the target dose range of 25-35% of total calories.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized LC-FAOD Major Clinical Events (MCEs) Rate: 18 Months Pre- and Entire UX007 Period Comparison for UX007-CL201-Rollover CohortTime frame: Pre-UX007 treatment period (up to 18 months) and post-UX007 treatment period (up to 2072 days)
  2. Annualized LC-FAOD MCEs Rate: 18 Months Pre- and Entire UX007 Period Comparison for IST/Other Cohort and Triheptanoin-Naïve CohortTime frame: Pre-UX007 treatment period (up to 18 months) and post-UX007 treatment period (up to 2072 days)
  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious TEAEsTime frame: Post-UX007 treatment through the end of treatment (up to 2072 days) plus 30-35 days

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • Children's National Health System

    Washington D.C., District of Columbia

  • University of South Florida

    Tampa, Florida

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Boston Children's Hospital

    Boston, Massachusetts

  • Children's Hospital of Pittsburgh of UPMC

    Pittsburgh, Pennsylvania

  • Vanderbilt Medical Center

    Nashville, Tennessee

  • University of Utah

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • National Hospital for Neurology and Neurosurgery

    London, United Kingdom

  • Great Ormond Street Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.